FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553518033> ?p ?o ?g. }

• W2553518033 endingPage "4932" @default.
• W2553518033 startingPage "4932" @default.
• W2553518033 abstract "Abstract Introduction. Most acute myeloid leukemia (AML) patients with adverse prognosis either fail to achieve complete remission (CR) or relapse after short-term remission, new strategies are needed to improve therapeutic effect in these patients. Gene silencing via DNA methylation are frequent and reversible in high-risk AML, it provides the possibility to treat AML patients with DNA-hypomethylating agent. Decitabine alone has limited anti-leukemia effect and minimal toxicity. Studies demonstrated that decitabine prior to chemotherapy was likely to increase efficacy in AML. In this study, we investigated the effect of decitabine on susceptibility to cytotoxic drugs in chemoresistant AML cells. Efficacy and safety of decitabine prior to HAA regimen was evaluated in refractory, relapsed and high-risk AML patients. Methods. HL60, HL60/ADR, Kasumi-1, and primary AML cells were pre-treated with 1.0 μM decitabine for 72 hours, Sensitivities to harringtonine, adriamycin, cytarabine and the combination was determined by MTT, apoptosis was analyzed by flow cytometry. Protein expression was detected by western blotting. In clinic, Twenty-three patients were enrolled in decitabine prior to HAA regimen, and twenty-four patients in HAA alone. CR ratio was used to evaluate efficacy. Durations of neutrocytopenia or thrombcytopemia and infection incidence were observed to assess the safety. All of patients were followed up to 36 monthes, overall survival (OS) and disease-free survival (DFS) were calculated. Result. Decitabine increased sensitivity and apoptosis induced by harringtonine in HL60/ADR, as well as adriamycin and cytarabine in HL60/ADR and Kasumi-1 cells. But no change in sensitivity to each drug was observed in HL60, and sensitivity to harringtonine in Kasumi-1. The similar changes in sensitivity to adriamycin and cytarabine were also observed in primary AML cells from refractory patients (n=6). Cytotoxic effect of HAA was alsoincreaed by decitabine in HL60/ADR and Kasumi-1 cells (p=0.004, 0.018). Western blotting showed that decitabine decreased expression of DNMT1, activation of p53 and inhibition of c-Myc, Survivin and Bcl-2. In clinic, 16 (69.6%) patients in decitabine plus HAA regimen responded to the first course of induction therapy: 14 CR (60.9%) and 2 PR (8.7%). 1 in 2 patients with PR achieved CR after second course induction. It brought the overall CR was 65.2%. Otherwise, 10 (45.8%) patients in HAA regimen alone responded to the first induction: 7 CR (29.2%) and 4 PR (16.7%), 3 in 4 patients with PR achieved CR after the second induction, and overall CR reached 41.7%. The first-cycle CR ratio in decitabine plus HAA was higher than that in HAA alone (p=0.041). Patients continued to receive chemotherapy alternatively combined with decitabine. The median OS was 14 months in chemotherapy plus decitabine, 6 months in chemotherapy alone, and median DFS were 18 and 5 months in the former and latter. No significant difference was observed in the time of neutrophil (p=0.832, 0.631) or platelet recovery (p=0.798, 0.544) after induction and intensification therapy. The incidences of infection were also similar (p=0.724, 0.697). The clinic data indicated that decitabine plus HAA regimenit was efficacy and well-tolerated to treat refractory AML patients. Conclusion. Our results demonstrated that decitabine increased cytotoxic effect against chemoresistant AML cells. Combination of decitabine and HAA was safe and efficacy to treat refractory/relapsed AML. These findings support clinic protocols based on decitabine prior to chemotherapy to overcome resistance and improve therapeutic efficacy in AML patients. Disclosures Carter: PrismBiolab: Research Funding." @default.
• W2553518033 created "2016-11-30" @default.
• W2553518033 creator A5010298865 @default.
• W2553518033 creator A5032457247 @default.
• W2553518033 creator A5033207412 @default.
• W2553518033 creator A5043267366 @default.
• W2553518033 creator A5049131970 @default.
• W2553518033 creator A5051764626 @default.
• W2553518033 creator A5053447705 @default.
• W2553518033 creator A5053706461 @default.
• W2553518033 creator A5055111936 @default.
• W2553518033 creator A5070046055 @default.
• W2553518033 creator A5071773009 @default.
• W2553518033 creator A5075486072 @default.
• W2553518033 creator A5077083856 @default.
• W2553518033 creator A5082138222 @default.
• W2553518033 creator A5090223238 @default.
• W2553518033 date "2015-12-03" @default.
• W2553518033 modified "2023-10-16" @default.
• W2553518033 title "The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients" @default.
• W2553518033 doi "https://doi.org/10.1182/blood.v126.23.4932.4932" @default.
• W2553518033 hasPublicationYear "2015" @default.
• W2553518033 type Work @default.
• W2553518033 sameAs 2553518033 @default.
• W2553518033 citedByCount "0" @default.
• W2553518033 crossrefType "journal-article" @default.
• W2553518033 hasAuthorship W2553518033A5010298865 @default.
• W2553518033 hasAuthorship W2553518033A5032457247 @default.
• W2553518033 hasAuthorship W2553518033A5033207412 @default.
• W2553518033 hasAuthorship W2553518033A5043267366 @default.
• W2553518033 hasAuthorship W2553518033A5049131970 @default.
• W2553518033 hasAuthorship W2553518033A5051764626 @default.
• W2553518033 hasAuthorship W2553518033A5053447705 @default.
• W2553518033 hasAuthorship W2553518033A5053706461 @default.
• W2553518033 hasAuthorship W2553518033A5055111936 @default.
• W2553518033 hasAuthorship W2553518033A5070046055 @default.
• W2553518033 hasAuthorship W2553518033A5071773009 @default.
• W2553518033 hasAuthorship W2553518033A5075486072 @default.
• W2553518033 hasAuthorship W2553518033A5077083856 @default.
• W2553518033 hasAuthorship W2553518033A5082138222 @default.
• W2553518033 hasAuthorship W2553518033A5090223238 @default.
• W2553518033 hasBestOaLocation W25535180331 @default.
• W2553518033 hasConcept C104317684 @default.
• W2553518033 hasConcept C126322002 @default.
• W2553518033 hasConcept C143998085 @default.
• W2553518033 hasConcept C150194340 @default.
• W2553518033 hasConcept C190727270 @default.
• W2553518033 hasConcept C2776012956 @default.
• W2553518033 hasConcept C2776239401 @default.
• W2553518033 hasConcept C2776694085 @default.
• W2553518033 hasConcept C2778041864 @default.
• W2553518033 hasConcept C2778461978 @default.
• W2553518033 hasConcept C2778729363 @default.
• W2553518033 hasConcept C2780235182 @default.
• W2553518033 hasConcept C2781413609 @default.
• W2553518033 hasConcept C55493867 @default.
• W2553518033 hasConcept C71924100 @default.
• W2553518033 hasConcept C86803240 @default.
• W2553518033 hasConcept C98274493 @default.
• W2553518033 hasConceptScore W2553518033C104317684 @default.
• W2553518033 hasConceptScore W2553518033C126322002 @default.
• W2553518033 hasConceptScore W2553518033C143998085 @default.
• W2553518033 hasConceptScore W2553518033C150194340 @default.
• W2553518033 hasConceptScore W2553518033C190727270 @default.
• W2553518033 hasConceptScore W2553518033C2776012956 @default.
• W2553518033 hasConceptScore W2553518033C2776239401 @default.
• W2553518033 hasConceptScore W2553518033C2776694085 @default.
• W2553518033 hasConceptScore W2553518033C2778041864 @default.
• W2553518033 hasConceptScore W2553518033C2778461978 @default.
• W2553518033 hasConceptScore W2553518033C2778729363 @default.
• W2553518033 hasConceptScore W2553518033C2780235182 @default.
• W2553518033 hasConceptScore W2553518033C2781413609 @default.
• W2553518033 hasConceptScore W2553518033C55493867 @default.
• W2553518033 hasConceptScore W2553518033C71924100 @default.
• W2553518033 hasConceptScore W2553518033C86803240 @default.
• W2553518033 hasConceptScore W2553518033C98274493 @default.
• W2553518033 hasIssue "23" @default.
• W2553518033 hasLocation W25535180331 @default.
• W2553518033 hasOpenAccess W2553518033 @default.
• W2553518033 hasPrimaryLocation W25535180331 @default.
• W2553518033 hasRelatedWork W1980460837 @default.
• W2553518033 hasRelatedWork W2122782605 @default.
• W2553518033 hasRelatedWork W2523150743 @default.
• W2553518033 hasRelatedWork W2530906933 @default.
• W2553518033 hasRelatedWork W2553518033 @default.
• W2553518033 hasRelatedWork W2568879918 @default.
• W2553518033 hasRelatedWork W3163450469 @default.
• W2553518033 hasRelatedWork W3174719071 @default.
• W2553518033 hasRelatedWork W4224925603 @default.
• W2553518033 hasRelatedWork W4312049268 @default.
• W2553518033 hasVolume "126" @default.
• W2553518033 isParatext "false" @default.
• W2553518033 isRetracted "false" @default.
• W2553518033 magId "2553518033" @default.
• W2553518033 workType "article" @default.